These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 29501835)
1. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Rao M; Valentini D; Zumla A; Maeurer M Int J Infect Dis; 2018 Apr; 69():78-84. PubMed ID: 29501835 [TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
3. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection. Zhu C; Cai Y; Zhu J; Zhang L; Xing A; Pan L; Jia H; Mo S; Feng CG; Shen H; Chen X; Zhang Z Tuberculosis (Edinb); 2019 Sep; 118():101861. PubMed ID: 31526947 [TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens. Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383 [TBL] [Abstract][Full Text] [Related]
6. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model. de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis. Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554 [TBL] [Abstract][Full Text] [Related]
8. Suberoylanilide hydroxamic acid, a novel histone deacetylase inhibitor, improves the development and acetylation level of miniature porcine handmade cloning embryos. Sun JM; Cui KQ; Li ZP; Lu XR; Xu ZF; Liu QY; Huang B; Shi DS Reprod Domest Anim; 2017 Oct; 52(5):763-774. PubMed ID: 28432707 [TBL] [Abstract][Full Text] [Related]
9. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Nikonenko BV; Samala R; Einck L; Nacy CA Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure. Qiu X; Rong X; Yang J; Lu Y BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701 [TBL] [Abstract][Full Text] [Related]
11. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646 [TBL] [Abstract][Full Text] [Related]
13. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis. Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266 [TBL] [Abstract][Full Text] [Related]
14. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012 [TBL] [Abstract][Full Text] [Related]
15. Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis. Cao R; Teskey G; Islamoglu H; Abrahem R; Munjal S; Gyurjian K; Zhong L; Venketaraman V Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126957 [No Abstract] [Full Text] [Related]
16. Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment. Burianova I; Kuzelova K; Mitrovsky O; Spicka I; Stockbauer P; Zackova M Neoplasma; 2017; 64(2):228-237. PubMed ID: 28043150 [TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of nontuberculous mycobacteria from patients with pulmonary tuberculosis in Ghana. Otchere ID; Asante-Poku A; Osei-Wusu S; Aboagye SY; Yeboah-Manu D Int J Mycobacteriol; 2017; 6(1):70-75. PubMed ID: 28317808 [TBL] [Abstract][Full Text] [Related]
18. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. Maggisano V; Puppin C; Celano M; D'Agostino M; Sponziello M; Micali S; Navarra M; Damante G; Filetti S; Russo D Endocrine; 2014 Feb; 45(1):148-52. PubMed ID: 23636804 [TBL] [Abstract][Full Text] [Related]
19. Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641. D'Addio SM; Reddy VM; Liu Y; Sinko PJ; Einck L; Prud'homme RK Mol Pharm; 2015 May; 12(5):1554-63. PubMed ID: 25811733 [TBL] [Abstract][Full Text] [Related]
20. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles. Kumarasingam K; Vincent M; Mane SR; Shunmugam R; Sivakumar S; Uma Devi KR Int J Mycobacteriol; 2018; 7(1):84-88. PubMed ID: 29516891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]